Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1097-0142(19981101)83:9<1917::AID-CNCR6>3.0.CO;2-1PMID 9806649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic factors in gastric carcinoma.

  1997cited by this paper
• A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

  1996cited by this paper
• The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers.

  1996cited by this paper
• Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.

  1996cited by this paper
• Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.

  1996cited by this paper
• Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.

  1996cited by this paper
• Expression of p53 protein as a prognostic factor in patients with gastric cancer.

  1996cited by this paper
• Adjuvant and neoadjuvant therapy for gastric cancer.

  1996cited by this paper
• The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma

  1995cited by this paper
• Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.

  1995cited by this paper
• Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.

  1995cited by this paper
• Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.

  1995cited by this paper
• Implications of the p53 tumor-suppressor gene in clinical oncology.

  1995cited by this paper
• The role of p53 in cell-cycle control and apoptosis: implications for cancer.

  1995cited by this paper
• An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms

  1994cited by this paper
• Preoperative chemotherapy of locally advanced gastric cancer.

  1994cited by this paper
• The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma.

  1994cited by this paper
• Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.

  1993cited by this paper
• Prognostic factors in gastric carcinoma. Results of the German gastric carcinoma study 1992

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• High levels of p53 protein in UV-irradiated normal human skin.

  1993cited by this paper
• Expression of p53 protein in colorectal cancer and its relationship to short‐term prognosis

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• New developments in the treatment of gastric carcinoma.

  1991cited by this paper
• Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines.

  1991cited by this paper
• Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis.

  1991cited by this paper
• Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

  1991cited by this paper
• New developments in the treatment of gastric carcinoma.

  1990cited by this paper
• Estimates of the worldwide frequency of sixteen major cancers in 1980

  1988cited by this paper
• Primer of biostatistics : statistical software program version 6.0

  1981cited by this paper
• Unregulated emissions from catalyst-equipped cars: EPA overview.

  1975cited by this paper

• The critical role of circular RNAs in drug resistance in gastrointestinal cancers

  2023cites this paper
• Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair

  2021cites this paper
• Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma

  2020cites this paper
• Silencing of the ARK5 gene reverses the drug resistance of multidrug-resistant SGC7901/DDP gastric cancer cells

  2020cites this paper
• Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer

  2020cites this paper
• MCM 4 upregulation predicts poor prognosis in gastric cancer

  2019cites this paper
• Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine

  2019cites this paper
• Adapting and Surviving: Intra and Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells

  2019cites this paper
• Gender Differences in Gastric Cancer Survival: 99,922 Cases Based on the SEER Database

  2019cites this paper
• HNRNPC as a candidate biomarker for chemoresistance in gastric cancer

  2016cites this paper
• An Overview on Factors Underlying Gastric Cancer; Strategies for its Management With Particular Reference to Diet

  2016cites this paper
• Biological prognostic parameters in gastric carcinomas.

  2014cites this paper
• Relationship between P53 Status and Response to Chemotherapy in Patients with Gastric Cancer: A Meta-Analysis

  2014cites this paper
• Genetics/genomics/proteomics of gastric adenocarcinoma.

  2013cites this paper
• A review on biomarkers for prediction of treatment outcome in gastric cancer.

  2013cites this paper
• Expression Profile as Predictor of Relapse after Adjuvant Treatment in Gastric Cancer

  2012cites this paper
• The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients.

  2010cites this paper
• The Potential for Serum p53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer

  2010cites this paper
• New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.

  2010cites this paper
• Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives.

  2009cites this paper
• Gastric cancer.

  2009cites this paper
• Allelic Imbalance at p53 and Microsatellite Instability Are Predictive Markers for Resistance to Chemotherapy in Gastric Carcinoma

  2009cites this paper
• Prognostic Significance of p53 and Ki67 Proteins Expression in Greek Gastric Cancer Patients

  2009cites this paper
• Systemic treatment of gastric cancer.

  2009cites this paper
• Biomarkers of response to therapy in oesophago-gastric cancer

  2008cites this paper
• Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer

  2007cites this paper
• Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges

  2007cites this paper
• Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.

  2006cites this paper
• The role of systemic therapy for localised gastric cancer.

  2006cites this paper
• Molecular Markers for Gastric Adenocarcinoma

  2006cites this paper
• The prognostic significance of p53, p27kip1, p21waf1, HER‐2/neu, and Ki67 proteins expression in gastric cancer: A clinicopathological and immunohistochemical study of 121 Arab patients

  2005cites this paper
• Gastric cancer.

  2005cites this paper
• Expression of P53 Protein and Dna Flow Cytometry in Gastric Adenocarcinoma: Implications in Patients Treated with Adjuvant Etoposide, Adriamycin and Cisplatin

  2005cites this paper
• Quantitative analysis of p53 expression and cell proliferation in gastric carcinomas. An immunohistochemical study.

  2004cites this paper
• p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer

  2004cites this paper
• Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma

  2004cites this paper
• The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.

  2004cites this paper
• Enhanced TGFalpha-EGFR expression and P53 gene alterations contributes to gastric tumors aggressiveness.

  2004cites this paper
• TP53 and gastric carcinoma: A review

  2003cites this paper
• Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer

  2003cites this paper
• Molecular Analysis of Therapy Resistance in Gastric Cancer

  2003cites this paper
• Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.

  2003cites this paper
• Tumor p53 status and response to topoisomerase II inhibitors.

  2003cites this paper
• Apoptosis and apoptosis-associated gene products related to the response to neoadjuvant chemotherapy for gastric cancer.

  2002cites this paper
• Chemotherapy options for gastric cancer.

  2002cites this paper
• Clinical Potential of Biological Response Modifiers Combined with Chemotherapy for Gastric Cancer

  2002cites this paper
• Molecular markers predictive of response to chemotherapy in gastrointestinal tumors.

  2001cites this paper
• Influence of TP 53 Gene Alterations and c-erbB2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer 1

  2001cites this paper
• Molecular mechanisms involved in the pathogenesis of gastric carcinoma: interactions between genetic alterations, cellular phenotype and cancer histotype.

  2001cites this paper
• Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer.

  2001cites this paper
• Angiogenesis and Apoptosis‐Related Protein (p53, bcl‐2, and bax) Expression Versus Response of Gastric Adenocarcinomas to Paclitaxel and Carboplatin Chemotherapy

  2001cites this paper
• Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

  2001cites this paper
• Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma.

  2000cites this paper
• Pro‐apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer

  2000cites this paper
• Apoptosis Induced by Doxorubicin in Neurotumor Cells Is Divorced from Drug Effects on Ceramide Accumulation and May Involve Cell Cycle‐Dependent Caspase Activation

  2000cites this paper
• P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.

  2000cites this paper
• Preventing Recurrence of GI Cancer. Postgraduate Course held during the UEGW ’99, Rome, November 14, 1999

  2000cites this paper
• Changes in P‐glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53

  2000cites this paper
• Does p53 status influence tumor response to anticancer therapies?

  2000cites this paper
• Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity.

  2000cites this paper
• Loss of Heterozygosity and Microsatellite Instability as Predictive Markers for Neoadjuvant Treatment in Gastric Carcinoma 1

  2000cites this paper
• Effectiveness of immunochemotherapy for gastric cancer: a review of the current status.

  1999cites this paper
• Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma.

  1999cites this paper
• Nuovi Orientamenti Nel Trattamento Chemioterapico Del Carcinoma Gastrico

  1999cites this paper
• Role of nitric oxide in cancer biology.

  1999cites this paper
• Expression of p53 Protein and Prognosis in Gastric Carcinoma

  1999cites this paper